Do we really need all these new antidepressants? Weighing the options

Journal of Practical Psychiatry and Behavioral Health

Volumn 3, Issue 1, 1997, Pages 3-17

  Thase, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antidepressants; Bupropion; Mirtazapine; Monoamine oxidase inhibitors; Nefazodone; Selective serotonin reuptake inhibitors; Trazodone; Tricyclic antidepressants; Venlafaxine

Indexed keywords

EID: 0342592381     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-199701000-00001     Document Type: Article

References (93)

1. Thase ME, Kupfer DJ. Recent developments in pharmacotherapy of mood disorders. J Consult Clin Psychol 1996;64:646-59.
2. Depression Guideline Panel. Depression in primary care, Vol 2. Clinical practice guideline, Number 5. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; April 1993. AHCPR Publication No. 93-0551.
3. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl 6):12-21.
4. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 1993;150:571-7.
5. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268:3441-5.
6. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992;53(suppl):13-20.
7. Thase ME, Howland R. Biological processes in depression: Updated review and integration. In: Beckham E, ed. Handbook of depression. New York, NY: Guilford Publications; 1995:213-79.
8. Thase ME, Simons AD, Reynolds CF III. Abnormal electroencephalographic sleep profiles in major depression: Association with response to cognitive behavior therapy. Arch Gen Psychiatry 1996;53:99-108.
9. Thase ME, Dube S, Bowler K, et al. Hypothalamic-pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients. Am J Psychiatry 1996;153:886-91.
10. Wilner P. Animal models as simulations of depression. Trends Pharmacol Sci 1991;12:131-6.
11. Weiss JM. Stress-induced depression: Critical neurochemical and electrophysiological changes. In: Madden J, ed. Neurobiology of learning, emotion, and affect. New York, NY: Raven Press; 1991:123-54.
12. McKinney WT. Animal models. In: Paykel E, ed. Handbook of affective disorders, 2nd edition. New York, NY: Guilford Press; 1992:209-17.
13. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010.
14. Thase ME. Antidepressant options: Venlafaxine in perspective. J Clin Psychopharmacol 1996;16(suppl 2):10S-18S.
15. Potter WZ. Adrenoreceptors and serotonin receptor function: Relevance to antidepressant mechanisms of action. J Clin Psychiatry 1996;57(suppl 4):4-8.
16. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56(suppl 6):3-11.
17. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633-42.
18. Nelson JC. Are the SSRIs really better tolerated than the TCAs for treatment of major depression? Psychiatr Ann 1994;24:628-31.
19. Hotopf M, Lewis G, Norman C. Are SSRIs a cost-effetive alternative to tricyclics? Br J Psychiatry 1996;168:404-9.
20. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DF, eds. Psychopharmacology: The fourth generation of progress. New York, NY: Raven Press: 1995;1081-97.
21. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-81.
22. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. Br J Psychiatry 1995;310:1433-38.
23. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmcol 1994;9:47-53.
24. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: Efficacy, safety and cost effectiveness. J Clin Psychiatry 1991;52(suppl 6):23-33.
25. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. Br Med J 1995;310:221-3.
26. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacol 1995;12:185-219.
27. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993;163:30-4.
28. Thase ME, Frank E, Mallinger A, Hamer T, Kupfer DJ. Treatment of imipramine resistant recurrent depression: III. Efficacy of monamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11.
29. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-6.
30. Laux G, VoIz HP, Moller HJ. New and older monoamine oxidase inhibitors: A comparative profile. CNS Drugs 1995;3(suppl 2):145-58.
31. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-Deprenyl: A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989;46:45-50.
32. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994;51:615-7.
33. Gram LF. Fluoxetine. N Engl J Med 1994:331:1354-61.
34. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8-11.
35. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study. Am J Psychiatry 1994;151:1372-4.
36. Beasley CM, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL. Possible monoamine oxidase inhibitor serotonin uptake inhibitor interaction - fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13:312-20.
37. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-57.
38. Nemeroff CB, DeVane CL, Pollock BG. New antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
39. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 1996;16:273-85.
40. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996;16:1-11.
41. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
42. von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-12.
43. Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K. Absence of a sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996;57(suppl 1):24-8.
44. Tremaine LM, Wilner KD, Henry EB, et al. Absence of a biologically meaningful effect of sertraline on the pharmacokinetics and protein binding of tolbutaminde. Clin Pharmacokinet, in press.
45. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L. A placebo-controlled randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996;53:777-84.
46. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. Br Med J 1993;306:683-7.
47. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-8.
48. Danish University Antidepressant Group. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
49. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia: The venlafaxine French inpatient study group. Int Clin Psychopharmacol 1994;9(3):139-43.
50. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-9.
51. Stuppaeck CH, Geretsegger C, Whitworth AB, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994;14:241-6.
52. Kasper S, Heiden A. Do SSRIs differ in their antidepressant efficacy? Human Psychopharmacol 1995;10:S163-S172.
53. Pande AC, Saylor ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmcol 1993;8:243-5.
54. Rosenbaum JF. Managing selective-serotonin reuptake inhibitor-drug interactions in clinical practice. Clin Pharmacokinet 1995;25(suppl 1):53-9.
55. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-73.
56. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. JAMA 1996;275(24):1897-1902.
57. LePen C, Levy E, Ravily V, Beuzen JN, Meurgey F. The cost of treatment dropout in depression: A cost benefit analysis of fluoxetine vs. tricyclics. J Affective Disord 1994;31:1-18.
58. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995;56:30-1.
59. Joffe RT, Levitt AJ, Sokolov STH, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-5.
60. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment in patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry (in press).
61. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57:67-71.
62. Donoghue JM. A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom. J Serotonin Res 1995;1:47-51.
63. Gregor KL, Overhage JM, Coons SJ, McDonald RC. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clin Therapeutics 1994;16:306-15.
64. Sclar DA, Robinson LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412.
65. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: Peliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995;56:288-96.
66. Ascher JA, Cole JO, Colin JN, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
67. Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: A multicenter controlled trial. J Clin Psychiatry 1988;49:262-6.
68. Davidson J. Seizures and bupropion: A review. J Clin Psychiatry 1989;50:256-61.
69. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991;52:450-6.
70. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: Selection of an antidepressant. J Clin Psychiatry 1992;53(suppl 9):5-18.
71. Gardner EA, Johnston JA. Bupropion - an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985;5:24-9.
72. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-65.
73. Ferguson J, Cunningham L, Merideth C, et al. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry 1994;6:153-60.
74. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990;51:450-5.
75. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-3.
76. Goodnick PJ, Extein IL. Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1991;3:311-13.
77. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996;16(suppl 2):1S-9S.
78. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):21S-28S.
79. Ballenger JC. Clinical evaluation of venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):29S-36S.
80. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-8.
81. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in out-patients. Prog Neuropsychopharmacol 1996;20:57-71.
82. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-23.
83. Ereshefsky L. Drug-drug interactions involving antidepressants: Focus on venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):37S-53S.
84. Feighner JP. Cardiovascular safety in depressed patients: Focus on venlafaxine. J Clin Psychiatry 1995;56:574-9.
85. Ereshefsky L, Benefield WH Jr, Laird LK. Update on drug therapy for depression: Novel agents for the nineties. Prim Psychiatry 1995;2:28-36.
86. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996;57(suppl 2):31-8.
87. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53-62.
88. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with major depression. J Clin Psychiatry 1996;57(suppl 2):46-52.
89. Armitage R, Rush AJ, Trivedi M, Cain J, Roffwarg HP. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994;10:123-7.
90. Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995;56(suppl 6):37-42.
91. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychoparmacol 1995;10:19-23.
92. Montgomery SA. Safety of mirtazapine: A review. Int Clin Psychopharmacol 1995;10(suppl 4):37-45.
93. Kasper S. Clinical efficacy of mirtazapine: A review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995;10(suppl 4):25-35.